Drug Trial Radar · NCT04540770
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 31, 2021
Primary completion
Mar 4, 2022
Study completion Jan 19, 2024
Sponsor
- Lead sponsor
- HuniLife Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human, two-part, Phase 1 study that will characterize the safety, tolerability, PK, and immunogenicity of HuL001.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
HuL001Drug
Anti-ENO1 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency, severity, and causality of adverse events (AEs), including solicited local AEsTime frame: 70 Days in Part A and 84 Days in Part B
- Proportion of subjects who report clinically significant abnormal findings in physical examinationTime frame: 70 Days in Part A and 84 Days in Part B
- Change from baseline in blood pressureTime frame: 70 Days in Part A and 84 Days in Part B
- Change from baseline in respiratory rateTime frame: 70 Days in Part A and 84 Days in Part B
- Change from baseline in heart rateTime frame: 70 Days in Part A and 84 Days in Part B
- Change from baseline in body temperatureTime frame: 70 Days in Part A and 84 Days in Part B
- Change from baseline in hematology assessmentsTime frame: 70 Days in Part A and 84 Days in Part B
- Change from baseline in biochemistry assessmentsTime frame: 70 Days in Part A and 84 Days in Part B
- Change from baseline in electrocardiogram (ECG) results (including PR, QRS, QT, QTcF, and RR intervals)Time frame: 70 Days in Part A and 84 Days in Part B
- Tolerability of HuL001 in terms of frequency of events meeting the intra-cohort stopping criteria within the tolerability observation periodTime frame: 70 Days in Part A and 84 Days in Part B
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mackay Memorial Hospital
New Taipei City, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.